Humanigen (HGENQ) 10-Q 3 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 01, 2019
Document and Entity Information
Entity Registrant Name	HUMANIGEN, INC
Entity Central Index Key	0001293310
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		110,223,316
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 180	$ 814
Prepaid expenses and other current assets	479	485
Total current assets	659	1,299
Restricted cash	71	71
Total assets	730	1,370
Current liabilities:
Accounts payable	3,449	2,856
Accrued expenses	3,036	3,129
Advance notes	893	807
Notes payable to vendors	1,508	1,471
Total current liabilities	8,886	8,263
Convertible notes	1,395	1,217
Total liabilities	10,281	9,480
Stockholders' deficit:
Common stock, $0.001 par value: 225,000,000 shares authorized at March 31, 2019 and December 31, 2018; 110,148,316 and 109,897,526 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively	110	110
Additional paid-in capital	267,481	266,381
Accumulated deficit	(277,142)	(274,601)
Total stockholders' deficit	(9,551)	(8,110)
Total liabilities and stockholders' deficit	$ 730	$ 1,370

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	225,000,000	225,000,000
Common stock, shares issued	110,148,316	109,872,526
Common stock, shares outstanding	110,148,316	109,872,526

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating expenses:
Research and development	$ 359	$ 696
General and administrative	1,879	3,957
Total operating expenses	2,238	4,653
Loss from operations	(2,238)	(4,653)
Other income (expense):
Interest expense	(302)	(394)
Other expense, net	(1)	(3)
Reorganization items, net		(37)
Net loss	(2,541)	(5,087)
Other comprehensive income
Comprehensive loss	$ (2,541)	$ (5,087)
Basic and diluted net loss per common share	$ (0.02)	$ (0.10)
Weighted average common shares outstanding used to calculate basic and diluted net loss per common share	110,033,098	49,155,859

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating activities:
Net loss	$ (2,541)	$ (5,087)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		10
Noncash interest expense	301	393
Stock based compensation expense	697	2,675
Issuance of common stock for payment of compensation	48
Issuance of common stock in exchange for services	68
Changes in operating assets and liabilities:
Prepaid expenses and other assets	5	(25)
Accounts payable	592	(28)
Accrued Expenses	146	234
Net cash used in operating activities	(684)	(1,828)
Financing activities:
Net proceeds from issuance of common stock		2,601
Net proceeds from term loan		50
Proceeds from issuance of common stock upon exercise of options	50
Net cash provided by financing activities	50	2,651
Net (decrease) increase in cash, cash equivalents and restricted cash	(634)	823
Cash, cash equivalents and restricted cash, beginning of period	885	838
Cash, cash equivalents and restricted cash, end of period	251	1,661
Supplemental cash flow disclosure:
Cash paid for interest	1	1
Supplemental disclosure of non-cash investing and financing activities:
Conversion of notes payable and related accrued interest and fees to common stock		18,432
Issuance in stock options for payment of accrued compensation	195	303
Issuance of common stock for payment of accrued compensation	42
Issuance of common stock for payment of compensation	48
Issuance of common stock in exchange for services	$ 68

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balances at Dec. 31, 2017	$ 15	$ 238,246	$ (262,597)	$ (24,336)
Balances (in shares) at Dec. 31, 2017	14,946,712
Stock-based compensation expense		2,675		2,675
Conversion of notes payable and related accrued interest and fees to common stock	$ 76	18,356		18,432
Conversion of notes payable and related accrued interest and fees to common stock (in shares)	76,007,754
Issuance of common stock	$ 18	2,583		2,601
Issuance of common stock (in shares)	18,253,320
Issuance of stock options for payment of accrued compensation		303		303
Issuance of common stock for payment of compensation
Comprehensive loss			(5,087)	(5,087)
Balances at Mar. 31, 2018	$ 109	262,163	(267,684)	(5,412)
Balances (in shares) at Mar. 31, 2018	109,207,786
Balances at Dec. 31, 2018	$ 110	266,381	(274,601)	(8,110)
Balances (in shares) at Dec. 31, 2018	109,872,526
Stock-based compensation expense		697		697
Issuance of stock options for payment of accrued compensation		195		195
Issuance of common stock for payment of accrued compensation	57,432	42		42
Issuance of common stock for payment of compensation	35,926	48		48
Issuance of common stock in exchange for services	82,432	68		68
Exercise of common stock options	75,000	50		50
Comprehensive loss			(2,541)	(2,541)
Balances at Mar. 31, 2019	$ 110	$ 267,481	$ (277,142)	$ (9,551)
Balances (in shares) at Mar. 31, 2019	110,148,316

Nature of Operations

Nature of Operations	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	1. Nature of Operations Description of the Business The Company was incorporated on March 15, 2000 in California and reincorporated as a Delaware corporation in September 2001 under the name KaloBios Pharmaceuticals, Inc. Effective August 7, 2017, the Company changed its legal name to Humanigen, Inc. During February 2018, the Company completed the restructuring transactions announced in December 2017 and furthered its transformation into a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, potentially making these treatments safer, more effective and more efficiently administered. The Company’s primary focus is on improving the efficacy and safety of chimeric antigen receptor T-cell, also known as CAR-T, therapy through the prophylactic administration of its proprietary Humaneered ® There are currently no FDA approved therapies available for the prevention of the serious side effects associated with CAR-T therapies. Pre-clinical data generated in partnership with the Mayo Clinic indicates that the use of lenzilumab may prevent or significantly minimize the onset of both CAR-T induced neurologic toxicities (NT) and cytokine release syndrome (CRS) while also enhancing the proliferation and effector functions of the CAR-T therapy itself, thus simultaneously improving efficacy and potentially reducing relapse rates, a key issue with current CAR-T therapy where approximately half the patients who initially respond have relapsed within a year of therapy. The Company continues to advance the development of lenzilumab through setting up clinical trials that it expects will serve as the basis for registration in close collaboration with some of the leading and most experienced investigators in the CAR-T field. The Company is also exploring partnerships with established CAR-T companies as a potential means of accelerating the development and commercialization of lenzilumab in conjunction with their existing CAR-T offerings. The Company aims to position lenzilumab as an essential companion product to CAR-T therapy and a necessary part of the standard pre-conditioning drug regimen that all patients treated with CAR-T currently receive. Lenzilumab is a recombinant monoclonal antibody (mAb) that neutralizes soluble granulocyte-macrophage colony-stimulating factor (GM-CSF) a critical cytokine which is elevated early in the inflammatory cascade and is associated with serious and potentially life-threatening CAR-T-related side effects and in the growth of certain hematologic malignancies, solid tumors and other serious conditions. There is extensive evidence linking early elevation of GM-CSF to serious and potentially life-threatening side-effects in CAR-T therapy. Following CAR-T administration GM-CSF initiates a signaling cascade of inflammation that results in the trafficking and recruitment of myeloid cells to the tumor site. These myeloid cells then produce key downstream cytokines known to be associated with development of NT and CRS, further perpetuating the inflammatory cascade. Peer-reviewed publications in leading journals by well-recognized experts have shown that GM-CSF is a biomarker elevated in patients who suffer severe NT as a side-effect of CAR-T therapy. Pre-clinical studies have demonstrated lenzilumab’s effectiveness in preventing CRS and significantly reducing NT associated with CAR-T therapy. The data from these studies also shows an increase in CAR-T cell expansion when lenzilumab is administered prophylactically in combination with CAR-T. Ifabotuzumab is an anti-Eph Type-A receptor 3 (EphA3) mAb that has the potential for treating solid tumors, hematologic malignancies and serious pulmonary conditions. Anti-EphA3 as a CAR construct may also be useful in the treatment of a range of cancers. EphA3 is a tumor specific antigen expressed on the surface of a multitude of solid bulk tumor cells, tumor stroma cells and tumor vasculature in certain cancers. The Company completed the Phase I dose escalation portion of a Phase I/II clinical trial in ifabotuzumab in multiple hematologic malignancies for which the preliminary results were published in the journal Leukemia Research HGEN005 is a pre-clinical stage anti-human epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1) mAb. EMR1 is a therapeutic target for eosinophilic disorders. Eosinophils are a type of white blood cell. If too many are produced in the body, chronic inflammation and tissue and organ damage may result. Analysis of blood and bone marrow shows that surface expression of EMR1 is restricted to mature eosinophils and correlated with eosinophilia. Tissue eosinophils also express EMR1. In pre-clinical work, the Company has demonstrated that eosinophil killing is enhanced in the presence of HGEN005 and immune effector cells. A major limitation of current eosinophil targeted therapies is incomplete depletion of tissue eosinophils and/or lack of cell selectivity, which may mean that HGEN005 could offer promise in a range of eosinophil-driven diseases, such as eosinophilic asthma, eosinophilic esophagitis and eosinophilic granulomatosis with polyangiitis. The Company is considering developing a series of CAR constructs based on HGEN005 and may take or partner these constructs, if developed, into pre-clinical testing. The Company’s monoclonal antibody portfolio was developed with its proprietary, patent-protected Humaneered ® Liquidity and Going Concern The Company has incurred significant losses since its inception in March 2000 and had an accumulated deficit of $277.1 million as of March 31, 2019. At March 31, 2019, the Company had a working capital deficit of $8.2 million. To date, none of the Company’s product candidates has been approved for sale and therefore the Company has not generated any revenue from product sales. Management expects operating losses to continue for the foreseeable future. The Company will require additional financing in order to meet its anticipated cash flow needs during the next twelve months. As a result, the Company will continue to require additional capital through equity offerings, debt financing and/or payments under new or existing licensing or collaboration agreements. If sufficient funds are not available on acceptable terms when needed, the Company could be required to significantly reduce its operating expenses and delay, reduce the scope of, or eliminate one or more of its development programs. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, could materially harm its business, financial condition and results of operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Condensed Consolidated Financial Statements for the three months ended March 31, 2019 were prepared on the basis of a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business. The ability of the Company to meet its total liabilities of $10.3 million at March 31, 2019 and to continue as a going concern is dependent upon the availability of future funding. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Basis of Presentation The accompanying interim unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and on a basis consistent with the annual consolidated financial statements and include all adjustments necessary for the presentation of the Company’s condensed consolidated financial position, results of operations and cash flows for the periods presented. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. These financial statements have been prepared on a basis that assumes that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The December 31, 2018 Condensed Consolidated Balance Sheet was derived from the audited financial statements but does not include all disclosures required by U.S. GAAP. These interim financial results are not necessarily indicative of the results to be expected for the year ending December 31, 2019, or for any other future annual or interim period. The accompanying unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company’s 2018 Form 10-K. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results could differ materially from those estimates. The Company believes judgment is involved in determining the valuation of the fair value-based measurement of stock-based compensation, accruals and warrant valuations. The Company evaluates its estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Condensed Consolidated Financial Statements.

Chapter 11 Filing

Chapter 11 Filing	3 Months Ended
	Mar. 31, 2019
Financial Statement Presentation While in Chapter 11 [Abstract]
Chapter 11 Filing	2. Chapter 11 Filing On December 29, 2015, the Company filed a voluntary petition for bankruptcy protection under Chapter 11 of the U.S. Bankruptcy Code. The filing was made in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) (Case No. 15-12628 (LSS) (the “Bankruptcy Case”). The Company’s Plan of Reorganization filed with the Bankruptcy Court (the “Plan”) became effective June 30, 2016 and the Company emerged from its Chapter 11 bankruptcy proceedings. The reconciliation of certain proofs of claim filed against the Company in the Bankruptcy Case, including certain General Unsecured Claims, Convenience Class Claims and Other Subordinated Claims, is complete. As a result of its examination of the claims, the Company asked the Bankruptcy Court to disallow, reduce, reclassify, subordinate or otherwise adjudicate certain claims the Company believes are subject to objection or otherwise improper. On July 11, 2018, the Company filed an objection to the remaining claims. By objection, the Company sought to disallow in their entirety the remaining claims totaling approximately $0.5 million. On September 17, 2018 the Bankruptcy Court issued a Final Decree and Order to close the Bankruptcy Case and terminate the remaining claims and noticing services. For the three months ended March 31, 2018, Reorganization items, net consisted of the following charges related to the bankruptcy proceedings: Three months ended March 31, 2019 2018 Legal fees $ - $ 30 Professional fees - 7 Total reorganization items, net $ - $ 37 Cash payments for reorganization items totaled $0.1 million three months ended March 31, 2018.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies since those previously disclosed in the 2018 Annual Report. In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash”. ASU 2016-18 requires the inclusion of restricted cash with cash and cash equivalents when reconciling the beginning-of-the period and end-of-period total amounts shown on the statement of cash flows. The Company adopted the standard effective January 1, 2018. As a result of the adoption, the Company will no longer present the change within restricted cash in the consolidated statements of cash flows. See below for the composition of cash, cash equivalents and restricted cash shown on the statements of cash flow: March 31, 2019 2018 Cash and cash equivalents $ 180 $ 1,560 Restricted cash 71 101 Total cash, cash equivalents and restricted cash as shown on statement of cash flows $ 251 $ 1,661 In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The FASB subsequently issued ASU No. 2018-10 and 2018-11 in July 2018, which provide clarifications and improvements to ASU 2016-02 (collectively, the “new lease standard”). ASU No. 2018-11 provides the optional transition method which allows companies to apply the new lease standard at the adoption date instead of at the earliest comparative period presented and continue to apply the provisions of the previous lease standard in its annual disclosures for the comparative periods. The new lease standard requires lessees to present a right-of-use asset and a corresponding lease liability on the balance sheet. Additional footnote disclosures related to leases is also required. On January 1, 2019, the Company adopted the new lease standard using the optional transition method and certain other practical expedients. Under the practical expedient package elected, the Company is not required to reassess whether expired or existing contracts are or contain a lease; and is not required to reassess the lease classifications or reassess the initial direct costs associated with expired or existing leases. The new lease standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company will not recognize right of use assets or lease liabilities, and this includes not recognizing right of use assets or lease liabilities for existing short-term leases of those assets in transition. The Company elected the practical expedient to not separate lease and non-lease components for certain classes of assets. See Note 4 for a description of the Company’s current leases and their treatment under the new lease standard. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Non-Employee Share-Based Payment Accounting (Topic 718), or ASU 2018-07. ASU 2018-07, which simplifies the accounting for non-employee share-based payment transactions, specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. ASU 2018-07 is effective for public business entities for fiscal years beginning after December 15, 2018, and early adoption is permitted. The Company adopted ASU 2018-07 in the first quarter of 2019. The adoption of this standard had no impact on the Company’s unaudited interim condensed consolidated financial statements as all outstanding non-employee share-based awards had vested by December 31, 2018.

Leases

Leases	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Leases	4. Leases The Company leases an office-space under a month-to-month lease for $1,000 per month. Management has determined the lease term to be less than 12 months, including renewals, and therefore has not recorded a right-of-use asset and corresponding liability under the short-term lease recognition exemption. Lease costs for the first quarter of 2019 totaled $3,000 and are included in the Consolidated Statements of Operations. As described in Note 3, the Company has elected to adopt the transitional practical expedients, and was not required to reassess whether any existing or expired contracts contained embedded leases. The Company has not entered into any contracts during the 2019 fiscal year that contain an embedded lease.

Potentially Dilutive Securities

Potentially Dilutive Securities	3 Months Ended
	Mar. 31, 2019
Potentially Dilutive Securities
Potentially Dilutive Securities	5. Potentially Dilutive Securities The Company’s potentially dilutive securities, which include stock options, restricted stock units and warrants, have been excluded from the computation of diluted net loss per common share as the effect of including those securities would be to reduce the net loss per common share and be antidilutive. Therefore, the denominator used to calculate both basic and diluted net loss per common share is the same in each period presented. The following outstanding potentially dilutive securities have been excluded from the computations of diluted net loss per common share: As of March 31, 2019 2018 Options to purchase common stock 16,062,922 15,527,069 Warrants to purchase common stock 331,193 331,193 16,394,115 15,858,262

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	6. Fair Value of Financial Instruments Cash, accounts payable and accrued liabilities are carried at cost, which approximates fair value given their short-term nature. Marketable securities and cash equivalents are carried at fair value. The Company has money market funds of $71 at March 31, 2019 and December 31, 2018 that are reported as restricted cash on the balance sheet. The amortized cost of these funds equals their fair value as there were no unrealized gains or losses at March 31, 2019 or December 31, 2018. The fair value of financial instruments reflects the amounts that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable, and the third is considered unobservable, as follows: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Inputs other than those included in Level 1 that are directly or indirectly observable, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company measures the fair value of financial assets and liabilities using the highest level of inputs that are reasonably available as of the measurement date. The following tables summarize the fair value of financial assets that are measured at fair value and the classification by level of input within the fair value hierarchy: Fair Value Measurements as of March 31, 2019 (in thousands) Level 1 Level 2 Level 3 Total Investments: Money market funds $ 71 $ — $ — $ 71 Total assets measured at fair value $ 71 $ — $ — $ 71 Fair Value Measurements as of December 31, 2018 (in thousands) Level 1 Level 2 Level 3 Total Investments: Money market funds $ 71 $ — $ — $ 71 Total assets measured at fair value $ 71 $ — $ — $ 71

Debt

Debt	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Debt	7. Debt Notes Payable to Vendors On June 30, 2016, the Company issued promissory notes in an aggregate principal amount of approximately $1.2 million to certain claimants in accordance with the Plan. The notes are unsecured, bear interest at 10% per annum and are due and payable in full, including principal and accrued interest on June 30, 2019. As of March 31, 2019 and December 31, 2018, the Company has accrued $0.4 million and $0.3 million in interest related to these promissory notes, respectively. Advance Notes In June, July and August, 2018 the Company received an aggregate of $0.9 million of proceeds from advances made to the Company (the “Advance Notes”) by four different lenders including Dr. Cameron Durrant, the Company’s Chairman and Chief Executive Officer; Cheval Holdings, Ltd., an affiliate of Black Horse Capital, L.P., the Company’s controlling stockholder; and Ronald Barliant, a director of the Company (collectively the “Lenders”). The Advance Notes will accrue interest at a rate of 7% per year, compounded annually. The intention of the parties is that the amounts due under the Advance Notes will be converted automatically into the same type and class of securities as may be sold by the Company in a future financing transaction with an aggregate sales price of at least $5 million (a “Qualifying Financing”). The Advance Notes generally are not convertible at the option of the lender into the Company’s common stock until June 21, 2019 (the “Expiration Date”); however, if prior to completing a Qualifying Financing, the Company experiences a change of control or makes a public announcement that it has entered into a collaboration arrangement with a strategic partner relating to clinical studies of lenzilumab in connection with certain CAR-T therapies in a transaction that would not otherwise constitute a Qualifying Financing, the lenders may elect to convert the amounts due under the Advance Notes into the Company’s common stock at a conversion price of $0.45 per share. Additionally, if neither a Qualifying Financing nor a change of control has occurred by the Expiration Date, then at any time from and after the Expiration Date the Lenders may, at their option, convert the Advance Notes, plus any accrued and unpaid interest, into a number of shares of the Company’s common stock at the lesser of (i) the volume weighted average sales price per share over the 20 most recent trading days prior to the conversion or (ii) $0.45 per share. Convertible Notes Commencing September 19, 2018, the Company delivered a series of convertible promissory notes (the “Notes”) evidencing an aggregate of $2.5 million of loans made to the Company by six different lenders, including an affiliate of Black Horse Capital, L.P., the Company’s controlling stockholder. The Notes bear interest at a rate of 7% per annum and will mature on the earliest of (i) twenty-four months from the date the Notes are signed, (ii) the occurrence of any customary event of default, or (iii) the certain liquidation events including any dissolution or winding up of the Company or merger or sale by the Company of all or substantially all of its assets (in any case, a “Liquidation Event”). The Company plans to use the proceeds from the Notes for working capital. The Notes are convertible into equity securities in the Company in three different scenarios: If the Company sells its equity securities on or before the date of repayment of the Notes in any financing transaction that results in gross proceeds to the Company of at least $10 million (a “Qualified Financing”), the Notes will be converted into either (i) such equity securities as the noteholder would acquire if the principal and accrued but unpaid interest thereon (the “Conversion Amount”) were invested directly in the financing on the same terms and conditions as given to the financing investors in the Qualified Financing, or (ii) common stock at a conversion price equal to $0.45 per share (subject to ratable adjustment for any stock split, stock dividend, stock combination or other recapitalization occurring subsequent to the date of the Notes). If the Company sells its equity securities on or before the date of repayment of the Notes in any financing transaction that results in gross proceeds to the Company of less than $10 million (a “Non-Qualified Financing”), the noteholders may convert their remaining Notes into either (i) such equity securities as the noteholder would acquire if the Conversion Amount were invested directly in the financing on the same terms and conditions as given to the financing investors in the Non-Qualified Financing, or (ii) common stock at a conversion price equal to $0.45 per share (subject to ratable adjustment for any stock split, stock dividend, stock combination or other recapitalization occurring subsequent to the date of the Notes). The Notes may convert in the event the Company enters into or publicly announces its intention to consummate a Liquidation Event. Immediately prior to the completion of any such Liquidation Event, in lieu of receiving payment in cash, noteholders may convert the Conversion Amount into common stock at a conversion price equal to $0.45 per share (subject to ratable adjustment for any stock split, stock dividend, stock combination or other recapitalization occurring subsequent to the date of the Notes). The Advance Notes and Notes have an optional voluntary conversion feature in which the holder could convert the notes into the Company’s common stock at maturity at a conversion rate of $0.45 per share. The intrinsic value of this beneficial conversion feature was $1.7 million upon the issuance of the Advance Notes and Notes and was recorded as additional paid-in capital and as a debt discount which is accreted to interest expense over the term of the Advance Notes and Notes. Interest expense includes debt discount amortization of $0.2 million for the three -month period ended March 31, 2019. The Company evaluated the embedded features within the Advance Notes and Notes to determine if the embedded features are required to be bifurcated and recognized as derivative instruments. The Company determined that the Advance Notes and the Notes contain contingent beneficial conversion features (“CBCF”) that allow or require the holder to convert the Advance Notes and Notes to Company common stock at a conversion rate of $0.45 per share, but did not contain embedded features requiring bifurcation and recognition as derivative instruments. Upon the occurrence of a CBCF that results in conversion of the Advance Notes or Notes to Company common stock, the remaining unamortized discount will be charged to interest expense.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Contractual Obligations and Commitments As of March 31, 2019 there were no material changes to the Company’s contractual obligations from those set forth in the 2018 Annual Report. Guarantees and Indemnifications The Company has certain agreements with service providers with which it does business that contain indemnification provisions pursuant to which the Company typically agrees to indemnify the party against certain types of third-party claims. The Company accrues for known indemnification issues when a loss is probable and can be reasonably estimated. The Company would also accrue for estimated incurred but unidentified indemnification issues based on historical activity. As the Company has not incurred any indemnification losses to date, there were no accruals for or expenses related to indemnification issues for any period presented.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Equity	9. Stockholders’ Equity Restructuring Transactions As further described in the Company’s Form 10-K for the year ended December 31, 2018, on February 27, 2018, the Company completed a comprehensive restructuring of its outstanding indebtedness of approximately $18.4 million under a series of term loans (the “Term Loans”) with two lender groups, including affiliates of Black Horse Capital, L.P. and raised incremental new capital from Cheval Holdings, Ltd. At the closing of the restructuring, the Company: (i) in exchange for the satisfaction and extinguishment of the entire balance of the Company’s Term Loans and related accrued interest totaling $18.4 million, (a) issued an aggregate of 59,786,848 shares of Common Stock (the “New Lender Shares”), and (b) transferred and assigned to a joint venture controlled by one of the term loan lenders, all of the assets of the Company related to benznidazole (the “Benz Assets”), the Company’s former drug candidate; and (ii) issued to Cheval an aggregate of 32,028,669 shares of Common Stock for total consideration of $3.0 million. The conversion of the outstanding debt for Common Stock at closing of the restructuring was accounted for as a decrease to Long-term debt and an increase to Common stock and Additional paid-in capital in the amount of the liabilities outstanding at the time of conversion. In connection with the transfer of the Benz Assets to the joint venture, the joint venture partner paid certain amounts incurred by the Company after December 21, 2017 and prior to February 27, 2018 in investigating certain causes of action and claims related to or in connection with the Benz Assets. In addition, upon exercise of its rights under the terms of the joint venture, the joint venture partner assumed certain legal fees and expenses owed by the Company to its litigation counsel totaling $0.3 million. Since the Benz Assets had no carrying value on the Company’s Condensed Consolidated Balance Sheet, the Company’s initial investment in the joint venture was recorded at $0. Equity Financings On March 12, 2018, the Company issued 2,445,557 shares of its common stock for total proceeds of $1.1 million to accredited investors. On June 4, 2018, the Company issued 400,000 shares of its common stock for total proceeds of $0.2 million to an accredited investor. 2012 Equity Incentive Plan Under the Company’s 2012 Equity Incentive Plan, the Company may grant shares, stock units, stock appreciation rights, performance cash awards and/or options to employees, directors, consultants, and other service providers. For options, the per share exercise price may not be less than the fair market value of a Company common share on the date of grant. Awards generally vest and become exercisable over three to four years and expire 10 years from the date of grant. Options generally become exercisable as they vest following the date of grant. On March 9, 2018, the Board of Directors of the Company approved an amendment to the Company’s 2012 Equity Incentive Plan (the “Equity Plan”) to increase the number of shares of the Company’s common stock authorized for issuance under the Equity Plan by 16,050,000 shares, and to increase the annual maximum aggregate number of shares subject to stock option awards that may be granted to any one person under the Equity Plan during a calendar year to 7,500,000. A summary of stock option activity for the three months ended March 31, 2019 under all of the Company’s options plans is as follows: Options Weighted Average Exercise Price Outstanding at January 1, 2019 15,409,357 $ 0.95 Granted 728,610 1.10 Exercised (75,000 ) 0.67 Cancelled (expired) (45 ) 9.68 Outstanding at March 31, 2019 16,062,922 $ 0.96 The weighted average fair value of options granted during the three months ended March 31, 2019 was $0.80 per share. The Company valued the options granted using the Black-Scholes options pricing model and the following weighted-average assumption terms for the three months ended March 31, 2019: Three months ended March 31, 2019 Exercise price $0.84 - $1.30 Market value $0.84 - $1.30 Risk-free rate 2.49% - 2.59% Expected term 6 years Expected volatility 99.1% - 99.3% Dividend yield - Stock-Based Compensation The Company recorded stock-based compensation expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss as follows: Three months ended March 31, 2019 2018 General and administrative $ 697 $ 2,474 Research and development - 201 Total stock-based compensation $ 697 $ 2,675 At March 31, 2019, the Company had $2.4 million of total unrecognized stock-based compensation expense, net of estimated forfeitures, related to outstanding stock options that will be recognized over a weighted-average period of 1.4 years.

Savant Arrangements

Savant Arrangements	3 Months Ended
	Mar. 31, 2019
Savant Arrangements
Savant Arrangements	10. Savant Arrangements On the June 30, 2016 the Company and Savant Neglected Diseases, LLC (“Savant”) entered into an Agreement for the Manufacture, Development and Commercialization of Benznidazole for Human Use (the “MDC Agreement”), pursuant to which the Company acquired certain worldwide rights relating to benznidazole (the “Compound”). In addition, on the Effective Date the Company and Savant also entered into a Security Agreement (the “Security Agreement”), pursuant to which the Company granted Savant a continuing senior security interest in the assets and rights acquired by the Company pursuant to the MDC Agreement and certain future assets developed from those acquired assets. On the Effective Date, the Company issued to Savant a five year warrant (the “Warrant”) to purchase 200,000 shares of the Company’s Common Stock, at an exercise price of $2.25 per share, subject to adjustment. The Warrant is exercisable for 25% of the shares immediately and exercisable for the remaining shares upon reaching certain regulatory related milestones. As of March 31, 2019 the number of shares for which the Warrant is currently exercisable totals 100,000 shares at an exercise price of $2.25 per share. As a result of the FDA granting accelerated and conditional approval of a benznidazole therapy manufactured by a competitor for the treatment of Chagas disease and awarding such competitor a neglected tropical disease PRV in August 2017, the Company ceased development of benznidazole and re-evaluated the final two vesting milestones and concluded that the probability of achievement of these milestones had decreased to 0%. In July 2017, the Company commenced litigation against Savant alleging that Savant breached the MDC Agreement and seeking a declaratory judgement. Savant has asserted counterclaims for breaches of contract under the MDC Agreement and the Security Agreement. The dispute primarily concerns the Company’s right under the MDC Agreement to offset certain costs incurred by the Company in excess of the agreed upon budget against payments due Savant. See Note 10, below, for more information regarding the Savant litigation. The aggregate cost overages as of June 30, 2017 that the Company asserts are Savant’s responsibility total approximately $3.4 million, net of a $0.5 million deductible. The Company asserts that it is entitled to offset $2.0 million in milestone payments due Savant against the cost overages, such that as of June 30, 2017, Savant owed the Company approximately $1.4 million. As of March 31, 2019, the cost overages totaled $4.1 million such that Savant owed the Company approximately $2.1 million in cost overages. Such cost overages have been charged to Research and development expense as incurred. Recovery of such cost overages, if any, will be recorded as a reduction of Research and development expense in the period received. The $2.0 million in milestone payments due Savant are included in Accrued expenses in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2019 and December 31, 2018.

Litigation

Litigation	3 Months Ended
	Mar. 31, 2019
Litigation Settlement [Abstract]
Litigation	11. Litigation Savant Litigation On July 10, 2017, the Company filed a complaint against Savant Neglected Diseases, LLC (“Savant”) in the Superior Court for the State of Delaware, New Castle County (the “Delaware Court”). KaloBios Pharmaceuticals, Inc. v. Savant Neglected Diseases, LLC On July 12, 2017, Savant removed the case to the Bankruptcy Court, claiming that the action is related to or arises under the Bankruptcy Case from which the Company emerged in July 2016. On July 27, 2017, Savant filed an Answer and Counterclaims. Savant’s filing alleges breaches of contracts under the MDC Agreement and the Security Agreement, claiming that the Company breached its obligations to pay the milestone payments and other related representations and obligations. On August 1, 2017, the Company moved to remand the case back to the Delaware Court (the “Motion to Remand”). On August 2, 2017, Savant sent a foreclosure notice to the Company, demanding that it provide the Collateral as defined in the Security Agreement for inspection and possession on August 9, 2017, with a public sale to be held on September 1, 2017. The Company moved for a Temporary Restraining Order (the “TRO”) and Preliminary Injunction in the Bankruptcy Court on August 4, 2017. Savant responded on August 7, 2017. On August 7, 2017, the Bankruptcy Court granted the Company’s motion for a TRO, entering an order prohibiting Savant from collecting on or selling the Collateral, entering our premises, issuing any default notices to us, or attempting to exercise any other remedies under the MDC Agreement or the Security Agreement. The parties have stipulated to continue the provisions of the TRO in full force and effect until further order of the appropriate court. On January 22, 2018, Savant wrote to the Bankruptcy Court requesting dissolution of the TRO. On January 29, 2018, the Bankruptcy Court granted the Motion to Remand and denied Savant’s request to dissolve the TRO, ordering that any request to dissolve the TRO be made to the Delaware Court. On February 13, 2018 Savant made a letter request to the Delaware Superior Court to dissolve the TRO. Also on February 13, 2018, Humanigen filed its Answer and Affirmative defenses to Savant’s Counterclaims. On February 15, 2018 Humanigen filed a letter opposition to Savant’s request to dissolve the TRO and requesting a status conference. A hearing on Savant’s request to dissolve the TRO was held before the Delaware Superior Court on March 19, 2018. The Delaware Superior Court denied Savant’s request to dissolve the TRO and the TRO remains in effect. On April 11, 2018, Humanigen advised the Delaware Superior Court that it would meet and confer with Savant regarding a proposed case management order and date for trial. On April 26, 2018 the Delaware Superior Court so-ordered a proposed case management order submitted by the Company and Savant. The schedule in the case management order was modified by stipulation on August 24, 2018. On April 8, 2019, Humanigen moved to compel Savant to produce documents in response to Humanigen’s document requests. A hearing on the motion is currently scheduled for May 13, 2019. There have been no further proceedings in this matter to date.

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Event	12. Subsequent Event Convertible Note Financing Commencing on April 23, 2019, Humanigen, Inc. (the “Company”) delivered a series of convertible promissory notes (the “Convertible Notes”) evidencing an aggregate of $1.3 million of loans made to the Company by an investor group led by Sound View Capital LP. The Convertible Notes bear interest at a rate of 7.5% per annum and will mature on the earliest of (i) twenty-four months from the date the Notes are signed (the “Stated Maturity Date”), (ii) the occurrence of any customary event of default, or (iii) the certain liquidation events including any dissolution or winding up of the Company or merger or sale by the Company of all or substantially all of its assets (in any case, a “Liquidation Event”). The Company plans to use the proceeds from the Convertible Notes for working capital. The Convertible Notes are convertible into equity securities in the Company in four different scenarios: If the Company sells its equity securities on or before the Stated Maturity Date in any financing transaction that results in gross proceeds to the Company of at least $10,000,000 (a “Qualified Financing”) or the Company consummates a reverse merger or similar transaction, the Convertible Notes will be converted into either (i) (a) in the case of a Qualified Financing, such equity securities as the noteholder would acquire if the principal and accrued but unpaid interest thereon together with such additional amount of interest as would have been paid on the Convertible Notes if held to the Stated Maturity Date (the “Conversion Amount”) were invested directly in the financing on the same terms and conditions (including price) as given to the financing investors in the Qualified Financing or (b) in the case of a reverse merger, common stock at the same price per share paid by the buyer in such transaction (which in a stock for stock transaction, shall be based on the price per share used by the parties for purposes of setting the applicable exchange ration), or (ii) common stock at a conversion price equal to $1.25 per share (subject to ratable adjustment for any stock split, stock dividend, stock combination or other recapitalization occurring subsequent to the date of the Convertible Notes). If the Company sells its equity securities on or before the date of repayment of the Convertible Notes in any financing transaction that results in gross proceeds to the Company of less than $10,000,000 (a “Non-Qualified Financing”), the noteholders may convert their remaining Convertible Notes into either (i) such equity securities as the noteholder would acquire if the Conversion Amount were invested directly in the financing on the same terms and conditions (including price) as given to the financing investors in the Non-Qualified Financing, or (ii) common stock at a conversion price equal to $1.25 per share (subject to ratable adjustment for any stock split, stock dividend, stock combination or other recapitalization occurring subsequent to the date of the Convertible Notes). The Convertible Notes may convert in the event the Company enters into or publicly announces its intention to consummate a Liquidation Event. Immediately prior to the completion of any such Liquidation Event, in lieu of receiving payment in cash, noteholders may convert the Conversion Amount into common stock at a conversion price equal to $1.25 per share (subject to ratable adjustment for any stock split, stock dividend, stock combination or other recapitalization occurring subsequent to the date of the Convertible Notes). In addition, upon the six-month anniversary of the date the Convertible Notes are signed or such earlier time as the Company announces the execution of definitive agreements for certain material strategic transactions, noteholders may convert any portion of the outstanding principal amount of the Convertible Notes, together with (a) any unpaid and accrued interest on such principal amount to the date the noteholder’s notice of the noteholder’s intention to convert is received by the Company (the “Notice Date”), and (b) such additional amount of interest as would have been paid on such principal amount from the Notice Date to the Stated Maturity Date, into common stock at a conversion price equal to $1.25 per share (subject to ratable adjustment for any stock split, stock dividend, stock combination or other recapitalization occurring subsequent to the date of the Convertible Notes).

Chapter 11 Filing (Tables)

Chapter 11 Filing (Tables)	3 Months Ended
	Mar. 31, 2019
Chapter 11 Filing Tables
Schedule of Reorganization Items, Net	For the three months ended March 31, 2018, Reorganization items, net consisted of the following charges related to the bankruptcy proceedings: Three months ended March 31, 2019 2018 Legal fees $ - $ 30 Professional fees - 7 Total reorganization items, net $ - $ 37

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Schedule of composition of cash, cash equivalents and restricted cash	See below for the composition of cash, cash equivalents and restricted cash shown on the statements of cash flow: March 31, 2019 2018 Cash and cash equivalents $ 180 $ 1,560 Restricted cash 71 101 Total cash, cash equivalents and restricted cash as shown on statement of cash flows $ 251 $ 1,661

Potentially Dilutive Securiti_2

Potentially Dilutive Securities (Tables)	3 Months Ended
	Mar. 31, 2019
Potentially Dilutive Securities Tables
Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Common Share	The following outstanding potentially dilutive securities have been excluded from the computations of diluted net loss per common share: As of March 31, 2019 2018 Options to purchase common stock 16,062,922 15,527,069 Warrants to purchase common stock 331,193 331,193 16,394,115 15,858,262

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of fair value of financial assets and liabilities measured at fair value and classification by level of input	The following tables summarize the fair value of financial assets that are measured at fair value and the classification by level of input within the fair value hierarchy: Fair Value Measurements as of March 31, 2019 (in thousands) Level 1 Level 2 Level 3 Total Investments: Money market funds $ 71 $ — $ — $ 71 Total assets measured at fair value $ 71 $ — $ — $ 71 Fair Value Measurements as of December 31, 2018 (in thousands) Level 1 Level 2 Level 3 Total Investments: Money market funds $ 71 $ — $ — $ 71 Total assets measured at fair value $ 71 $ — $ — $ 71

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
Summary of stock option activity	A summary of stock option activity for the three months ended March 31, 2019 under all of the Company’s options plans is as follows: Options Weighted Average Exercise Price Outstanding at January 1, 2019 15,409,357 $ 0.95 Granted 728,610 1.10 Exercised (75,000 ) 0.67 Cancelled (expired) (45 ) 9.68 Outstanding at March 31, 2019 16,062,922 $ 0.96
Schedule of fair value-based measurement of stock options granted under the entity's stock plans estimated using Black-Scholes model	The Company valued the options granted using the Black-Scholes options pricing model and the following weighted-average assumption terms for the three months ended March 31, 2019: Three months ended March 31, 2019 Exercise price $0.84 - $1.30 Market value $0.84 - $1.30 Risk-free rate 2.49% - 2.59% Expected term 6 years Expected volatility 99.1% - 99.3% Dividend yield -
Schedule of total stock-based compensation expense recognized	The Company recorded stock-based compensation expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss as follows: Three months ended March 31, 2019 2018 General and administrative $ 697 $ 2,474 Research and development - 201 Total stock-based compensation $ 697 $ 2,675

Nature of Operations (Details)

Nature of Operations (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)item	Dec. 31, 2018USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 277,142	$ 274,601
Number of product candidates approved for sale | item	0
Total liabilities	$ 10,281	$ 9,480
Working capital deficit	$ 8,200

Chapter 11 Filing (Narrative) (

Chapter 11 Filing (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Jul. 11, 2018
Cash payment for reorganization items	$ 100
Subject To Review By Bankruptcy Court [Member]
Disallowed bankruptcy claims, amount		$ 500

Chapter 11 Filing (Reorganizati

Chapter 11 Filing (Reorganization Items, Net) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Chapter 11 Filing Reorganization Items Net Details
Legal fees		$ 30
Professional fees		7
Total reorganization items, net		$ 37

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Composition of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Cash and cash equivalents	$ 180	$ 814	$ 1,560
Restricted cash	71	71	101
Total cash, cash equivalents and restricted cash as shown on statement of cash flows	$ 251	$ 885	$ 1,661	$ 838

Leases (Details)

Leases (Details)	3 Months Ended
	Mar. 31, 2019USD ($)
Leases [Abstract]
Monthly lease	$ 1,000
Lease costs	$ 3,000

Potentially Dilutive Securiti_3

Potentially Dilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted net loss per common share	16,394,115	15,858,262
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted net loss per common share	16,062,922	15,527,069
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted net loss per common share	331,193	331,193

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Fair Value of Financial Assets) (Details) - Fair Value Measurements Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	$ 71	$ 71
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	71	71
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value
Estimate Of Fair Value Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	71	71
Estimate Of Fair Value Fair Value Disclosure [Member] | Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	$ 71	$ 71

Debt (Details)

Debt (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Sep. 19, 2018	Mar. 31, 2019	Aug. 31, 2018	Dec. 31, 2018	Jun. 30, 2016
Debt Instrument [Line Items]
Debt instrument amount			$ 5,000
Proceeds from advance notes			$ 900
Percentage of accrued interest			7.00%
Common stock conversion price			$ 0.45
Convertible Promissory Note [Member] | Black Horse Capital, L.P [Member]
Debt Instrument [Line Items]
Term loan interest rate	7.00%
Debt instrument amount	$ 2,500
Advance Notes [Member]
Debt Instrument [Line Items]
Common stock conversion price		$ 0.45
Intrinsic value of this beneficial conversion feature		$ 1,700
Debt discount amortization		200
Qualified Financing [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Proceeds from convertible debt		$ 10,000
Conversion price		$ 0.45
Non Qualified Financing [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Proceeds from convertible debt		$ 10,000
Conversion price		$ 0.45
Notes Payable To Vendors [Member]
Debt Instrument [Line Items]
Interest rate					10.00%
Notes payable to vendors					$ 1,200
Accrued interest		$ 400		$ 300

Stockholders' Equity (Equity In

Stockholders' Equity (Equity Incentive Plan) (Details) - USD ($)	Jun. 04, 2018	Mar. 12, 2018	Mar. 09, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 21, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common share issued	400,000	2,445,557		110,148,316		109,872,526
Total proceeds	$ 200,000	$ 1,100,000			$ 2,601,000
Authorized shares of Common Stock				225,000,000		225,000,000
Equity Incentive Plan Twenty Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period expiration				10 years
Additional shares authorized			7,500,000
Authorized shares of Common Stock			16,050,000
Equity Incentive Plan Twenty Twelve [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				4 years
Equity Incentive Plan Twenty Twelve [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				3 years
Black Horse Capital, L.P [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term Loan						$ 18,400,000
Stock issued						32,028,669
Total consideration						$ 3,000,000
Black Horse Capital, L.P [Member] | New Lender Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued						59,786,848
Benz Assets [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Legal fees							$ 300,000
Initial investment				$ 0

Stockholders' Equity (Stock Opt

Stockholders' Equity (Stock Option Activity) (Details)	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Options
Balance at the beginning of the period (in shares) | shares	15,409,357
Options granted (in shares) | shares	728,610
Options exercised (in shares) | shares	(75,000)
Options Cancelled (expired) (in shares) | shares	(45)
Balance at the end of the period (in shares) | shares	16,062,922
Weighted Average Exercise Price (Per Share)
Balance at the beginning of the period (in dollars per share) | $ / shares	$ 0.95
Options granted (in dollars per share) | $ / shares	1.10
Options Exercised (in dollars per share) | $ / shares	0.67
Options Cancelled (expired) (in dollars per share) | $ / shares	9.68
Balance at the ending of the period (in dollars per share) | $ / shares	$ 0.96

Stockholders' Equity (Weighted-

Stockholders' Equity (Weighted-Average Assumption) (Details)	3 Months Ended
	Mar. 31, 2019$ / shares
Dividend yield
Minimum [Member]
Exercise price	$ 0.84
Market value	$ 0.84
Risk-free rate	2.49%
Expected term	6 years
Expected volatility	99.10%
Maximum [Member]
Exercise price	$ 1.30
Market value	$ 1.30
Risk-free rate	2.59%
Expected volatility	99.30%

Stockholders' Equity (Stock-Bas

Stockholders' Equity (Stock-Based Compensation Expense Recognized) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 697	$ 2,675
Unrecognized compensation expense	$ 2,400
Weighted average period for recognition	1 year 15 days
Weighted average fair value of options granted	$ 0.80
General And Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 697	2,474
Research And Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense		$ 201

Savant Arrangements (Details)

Savant Arrangements (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended
	Jun. 30, 2016	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2017
Aggregate cost overages				$ 3,400
Net of duductible				500
Due to Savant		$ 2,000	$ 2,000	2,000
Savant Neglected Diseases, LLC [Member]
Number of shares called by warrant	200,000	100,000
Exercise price of warrant	$ 2.25	$ 2.25
Exercise period of warrant	5 years
Aggregate cost overages		$ 2,100
Due to Savant		$ 4,100
Due from Savant				$ 1,400
Savant Neglected Diseases, LLC [Member] | Exercisable Immediately [Member]
Percentage of warrants exercisable	25.00%

Litigation (Details)

Litigation (Details) - Savant Neglected Diseases, LLC [Member] $ in Thousands	1 Months Ended
	Jun. 30, 2017USD ($)
Aggregate cost	$ 3,400
Deductible	500
Offset payment due	2,000
Amount owed	$ 1,400

Subsequent Event (Details)

Subsequent Event (Details) - Convertible Notes Payable [Member] - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Apr. 23, 2019	Mar. 31, 2019
Sound View Capital LP [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from convertible debt	$ 1,300
Interest rate	7.50%
Debt Term	24 months
Qualified Financing [Member]
Subsequent Event [Line Items]
Proceeds from convertible debt		$ 10,000
Conversion price		$ 0.45
Qualified Financing [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from convertible debt	$ 10,000
Conversion price	$ 1.25
Non Qualified Financing [Member]
Subsequent Event [Line Items]
Proceeds from convertible debt		$ 10,000
Conversion price		$ 0.45
Non Qualified Financing [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from convertible debt	$ 10,000
Conversion price	$ 1.25
Subsequent to date of Convertible Notes [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Conversion price	$ 1.25